Clinical trials: Patients With ST-elevated Myocardial Infarction
Diabete Mellitus, Heart Failure
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
This study is investigating how the medication Empagliflozin affects the heart's structure and function in patients with heart disease.
- Conditions
- Diabete Mellitus, Heart Failure, Remodeling, Left Ventricle
- Trial name
- EMPA-DMMI (NCT07169981)
- Testing
- Empagliflozin 10 MG [Jardiance], empagliflozin (Jardiance) 25 mg
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Acute Coronary Syndrome, ST Segment Elevation Myocardial Infarction
MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction
This is a prospective, randomized, active control, single-blind, non-inferiority, multicenter clinical trial. 148 subjects will be registered at up to 10 Spanish sites. Subjects will be followed for 5 years.
- Conditions
- Acute Coronary Syndrome, ST Segment Elevation Myocardial Infarction, Stent
- Trial name
- MAGSTEMI (NCT03234348)
- Testing
- Percutaneous coronary intervention
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Hospital Clinic of Barcelona
Acute Chest Pain, NSTEMI - Non-ST Segment Elevation MI
Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)
The PRESC1SE-MI study compares two algorithms for triage of patients presenting with chest pain and symptoms of heart attack (myocardial infarction) to the emergency department.
- Trial name
- PRESC1SE-MI (NCT05649384)
- Testing
- European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm, European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm
- Where
- 20 sites in United States, Australia and 9 more
- Volunteers
- 64,374 people
- Sponsor
- University Hospital, Basel, Switzerland
Coronary Heart Disease, Percutaneous Coronary Intervention
Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction
The primary objective of this study is: comparison of a safety and effectiveness of third generation DES (biolimus A9 and everolimus) in patients with STEMI treated by primary PCI with OCT guidance.
- Trial name
- ROBUST (NCT00888758)
- Testing
- biolimus A9, everolimus
- Where
- Czechia
- Volunteers
- 400 people
- Sponsor
- Masaryk University
Coronary Artery Disease, Endothelial NO-synthase
Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease
The aim of this study is measurement of expression and activity of RBC eNOS in different clinical cohorts of patients with coronary artery disease and acute coronary syndrome and to investigate the importance of the NO-stimulated…
- Trial name
- NCT02265016
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
ST Elevation Myocardial Infarction
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Estimated glomerular filtration rate(eGFR) is significantly reduced in patients with ST-segment elevation myocardial infarction (STEMI).
- Trial name
- NCT03984071
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Dongying Zhang
Heart Attack, Enlarged Heart
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack.
- Trial name
- NCT05305911
- Testing
- SGLT-2 inhibitors
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Minneapolis Heart Institute Foundation
ST Elevation Myocardial Infarction (STEMI), Acute Coronary Syndromes (ACS)
A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus Burden
This is a single-center, retrospective, propensity-score-matched observational study. It aims to compare the rate of immediate slow-flow or no-reflow after percutaneous coronary intervention (PCI) between drug-coated balloon…
- Trial name
- STEMI-DCB (NCT07806370)
- Testing
- Drug-Coated Balloon (DCB), Drug-Eluting Stent (DES)
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Xijing Hospital
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
ST Segment Elevated Myocardial Infarction
Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI
The study intends to evaluate the efficacy of early rhBNP on myocardial remodeling and reperfusion in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention
- Trial name
- NCT04033861
- Testing
- rhBNP, Control
- Where
- China
- Volunteers
- 352 people
- Sponsor
- RenJi Hospital
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.
- Conditions
- Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
- Trial name
- NCT01020383
- Testing
- ALX-0081, ReoPro®
- Where
- 39 sites in Austria, Belgium and 5 more
- Volunteers
- 364 people
- Sponsor
- Ablynx, a Sanofi company
Acute Myocardial Infarction, STEMI
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
A multi-center randomized post-approval evaluation of delivery of intracoronary hyperoxemic supersaturated Oxygen therapy for 60 minutes in anterior AMI patients with successful reperfusion (via PCI) within 6 hours after onset of…
- Trial name
- NCT04743245
- Testing
- TherOx DownStream System, PCI
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- TherOx
Coronary Artery Disease
High Ticagrelor Loading Dose in STEMI
Ticagrelor is a reversible direct acting P2Y12 antagonist, which has shown to be superior to clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic events.
- Trial name
- NCT01898442
- Testing
- Ticagrelor 180mg, Ticagrelor 270mg, Ticagrelor 360mg
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Florida
Acute Coronary Syndrome, Myocardial Infarction
OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
The goal of this clinical trial is to compare implementation of a Decision Support System (DSS) - aligned to the 2019 ESC/EAS Guidelines - in addition to routine clinical care versus routine clinical care without availability of…
- Trial name
- ZODIAC (NCT05844566)
- Testing
- Decision Support System (DSS)
- Where
- 42 sites in Italy, Spain and 1 more
- Volunteers
- 1,139 people
- Sponsor
- Imperial College London
Myocardial Ischemic-reperfusion Injury
Immunometabolic Pattern of Intermittent Hypoxia During ST-segment Elevation Myocardial Infarction
The aim of this study is to characterize the protective pattern of intermittent hypoxia, angina pectoris and remote ischemic conditioning, in reperfusion injury by determining and monitoring the plasma immunometabolic parameters…
- Trial name
- NCT05230966
- Testing
- Remote Ischemic Conditioning (RIC)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Clinical Hospital Center Rijeka
Myocardial Infarction, Optical Coherence Tomography
Optical Coherence Tomography Examination in Acute Myocardial Infarction
Different plaque morphology may have an important effect on the prognosis of acute myocardial infarction (AMI), as recent studies show that patients with plaque rupture have a significantly higher risk of cardiac events compared…
- Trial name
- OCTAMI (NCT03593928)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Center for Cardiovascular Diseases
Myocardial Infarction
18F-PBR06/Total Body PET Imaging in Patients With STEMI
The study will use 18F-PBR06/uExplorer to study the activation of macrophages and systemic perfusion in patients with ST-segment elevation myocardial infarction (STEMI) or stable angina (SA).
- Trial name
- NCT05269446
- Testing
- percutaneous coronary intervention (PCI), total body PET/CT scan, Coronary Angiography (CAG)
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
STEMI - ST Elevation Myocardial Infarction
Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.
During the outbreak of COVID-19, for patients with acute ST-segment elevation myocardial infarction with unclear infection, the time of primary PCI is uncertain, and it is often expected to exceed 90 minutes or even 120 minutes.
- Trial name
- RESCUE-STEMI (NCT05354128)
- Testing
- Thrombolytic, percutaneous coronary stenting
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ya-Wei Xu
Percutaneous Coronary Intervention, No-reflow Phenomen
The RESTORE-SIRIO Randomized Controlled Trial
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for treating acute ST-segment elevation myocardial infarction (STEMI).
- Conditions
- Percutaneous Coronary Intervention, No-reflow Phenomen, Acute ST-segment Elevation Myocardial Infarction
- Trial name
- RESTORE-SIRIO (NCT02405130)
- Testing
- intracoronary epinephrine, no intracoronary epinephrine
- Where
- Germany
- Sponsor
- Heinrich-Heine University, Duesseldorf